Effects of riociguat on right ventricular size and function in pulmonary arterial hypertension (RIVER II): a prospective, phase IV study [PDF]
Respiratory ResearchBackground Pulmonary arterial hypertension (PAH) is characterized by right ventricular (RV) pressure overload, dilatation and dysfunction, which are key prognostic determinants.
Satenik Harutyunova +9 more
doaj +2 more sources
Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
Pulmonary Circulation, 2022 Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in ...
Hidekazu Ishida, Biagio Castaldi
exaly +2 more sources
Retrospective evaluation of Selexipag monotherapy on pulmonary hemodynamics in newly diagnosed, treatment-naïve patients with chronic thromboembolic pulmonary hypertension prior to balloon pulmonary angioplasty [PDF]
International Journal of Cardiology: Heart & VasculatureBackground: Selexipag has been approved for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in Japan since April 2021; however, its hemodynamic effects in treatment-naïve patients with inoperable CTEPH prior to balloon pulmonary ...
Naohiro Komura +18 more
doaj +2 more sources
Practical management of riociguat in patients with pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, 2019 Riociguat is one of several approved therapies available for patients with pulmonary arterial hypertension (PAH). Treatment should be initiated and monitored at an expert center by a physician experienced in treating PAH, and the dose adjusted in the ...
Ioana R Preston +2 more
exaly +2 more sources
Riociguat Alleviates Cisplatin-Caused Kidney Injury by Suppressing Oxidative Stress and Inflammation [PDF]
BiologyBackground: Cisplatin (CP), a platinum-based chemotherapeutic agent, is widely used to treat cancer but causes nephrotoxicity. Riociguat, a soluble guanylate cyclase (sGC) stimulator that enhances the nitric oxide–sGC–cGMP signaling pathway, was ...
Yousuf M. Al Suleimani +5 more
doaj +2 more sources
Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) – a prospective cohort study [PDF]
BMC Pulmonary MedicineBackground For patients with chronic thromboembolic pulmonary hypertension (CTEPH), balloon pulmonary angioplasty (BPA) has been associated with superior reductions in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) when ...
Timothy Ho Him Kam +4 more
doaj +2 more sources
Pulmonary Circulation, 2022 Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by elevated pulmonary arterial pressure and organized thrombi within pulmonary arteries.
Takayuki Jujo Sanada +6 more
doaj +1 more source
Veterinary Sciences, 2023 Soluble guanylate cyclase (sGC) stimulator riociguat is a relatively novel therapeutic agent for pulmonary hypertension (PH) in human medicine. Riociguat induces endothelium-independent pulmonary artery (PA) relaxation by directly activating the sGC ...
Satoshi Kameshima +9 more
doaj +1 more source
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. [PDF]
PLoS ONE, 2012 The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signal-transduction pathway is impaired in many cardiovascular diseases, including pulmonary arterial hypertension (PAH).
Michaela Lang +10 more
doaj +1 more source
Biomedical Papers, 2021 Aims. The primary objective of the registry was to assess the impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension (CTEPH) that was inoperable or persistent/recurrent after ...
Pavel Jansa +5 more
doaj +1 more source